22: Baseline characteristics from the real-world CARINA study of patients with advanced renal cell carcinoma treated with cabozantinib after first-line checkpoint inhibitor-based combination therapy
Honorary Clinical Senior Lecturer, University of Glasgow Consultant in Medical Oncology, Beatson West of Scotland Cancer Centre Beatson West of Scotland Cancer Centre Glasgow, UK, United Kingdom
Background: Real-world data are needed to inform the optimal sequencing of therapies for advanced renal cell carcinoma (aRCC). CARINA (NCT04957160) is a UK-based, real-world, retrospective, non-interventional study of treatment sequencing and outcomes in patients with aRCC who received second-line (2L) treatment after first-line (1L) checkpoint inhibitor (CPI)-based combination therapy.
Methods: Data were collected from electronic prescribing records and medical records of patients (aged ≥18 years) diagnosed with aRCC who received 2L therapy after 1L CPI-based combination therapy at participating UK specialist centres. The primary study objective was to describe treatment sequence pathways. Efficacy outcomes were assessed as secondary outcomes. Here we report baseline characteristics of patients included in the CARINA study, ahead of the final study results.
Results: In total, 281 patients were enrolled, of whom 163 received 2L cabozantinib, at nine UK centres. Overall, 76.5% of patients were male, mean (standard deviation [SD]) age at aRCC diagnosis was 59.4 (10.1) years, and 87.5% had clear-cell aRCC (including aRCC with a clear-cell component). Among patients who received 2L cabozantinib, 75.5% were male, mean [SD] age was 58.7 (10.7) years, and 85.9% had clear-cell aRCC). Additional baseline characteristics are reported in the Table.
Conclusions: In the UK-based CARINA study, the available baseline characteristics of the overall population and the 2L cabozantinib subgroup were broadly consistent with data for the UK aRCC population. These baseline data support the relevance of the final results of CARINA, expected later in 2023.